Celiac disease laboratory tests: Difference between revisions

Jump to navigation Jump to search
Line 30: Line 30:
==== Oral tolerance tests: ====
==== Oral tolerance tests: ====
* Breath [[hydrogen]] excretion- increased in celiac disease
* Breath [[hydrogen]] excretion- increased in celiac disease
* Oral [[D-xylose]] tolerance test-
* Oral [[D-xylose]] tolerance test
** Decreased urinary [[D-xylose]] excretion
** Decreased urinary [[D-xylose]] excretion
** Decreased peak blood xylose levels
** Decreased peak blood xylose levels

Revision as of 14:23, 13 September 2017

Celiac disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Celiac disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Life Style Modifications
Pharmacotherapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Celiac disease laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Celiac disease laboratory tests

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Celiac disease laboratory tests

CDC on Celiac disease laboratory tests

Celiac disease laboratory tests in the news

Blogs onCeliac disease laboratory tests

Directions to Hospitals Treating Celiac disease

Risk calculators and risk factors for Celiac disease laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: : Iqra Qamar M.D.[2]

Overview

Laboratory findings consistent with the diagnosis of celiac disease include electrolyte abnormalities such as hypokalemia, hypocalcemia, hypomagnesemia, metabolic acidosis, hypoalbuminemia, hypoproteinemia, hypocholesterolemia and low serum carotene level. Hematologic findings include low folate and vitamin B-12 levels, low serum iron level and prothrombin time (PT) prolongation. Stool examination may show fat droplets on Sudan stain and a 72-hour fecal fat collection may be used for documentation of steatorrhea. Genetic testing is usually positive for HLA-DQ2 and HLA-DQ8. Serologic markers include IgA endomysial antibody (IgA EMA), IgA tissue transglutaminase antibody (IgA tTG), IgG tissue transglutaminase antibody (IgG tTG), IgA deamidated gliadin peptide (IgA DGP), and IgG deamidated gliadin peptide (IgG DGP). Serum IgA EMA and IgA tTG have the highest diagnostic accuracy. The IgA and IgG antigliadin antibodies (AGA) are not recommended for establishing diagnosis because of high rate of false positive results comparing to IgA tTG and IgA DGP assays.

Laboratory Findings

Laboratory findings consistent with the diagnosis of Celiac disease include:[1]

Electrolyte abnormalities:

Hematologic findings:

Stool examination:

Oral tolerance tests:

  • Breath hydrogen excretion- increased in celiac disease
  • Oral D-xylose tolerance test
    • Decreased urinary D-xylose excretion
    • Decreased peak blood xylose levels

Genetic testing:

Serologic Markers

Serological testing may be divided into 3 groups based upon antibodies against respective antigens:

  • IgA endomysial antibody (IgA EMA)
  • Anti-TTG antibody tests
    • IgA tissue transglutaminase antibody (IgA tTG)
    • IgG tissue transglutaminase antibody (IgG tTG)
  • Anti-gliadin antibody tests 
    • IgA deamidated gliadin peptide (IgA DGP)
    • IgG deamidated gliadin peptide (IgG DGP)

IgA endomysial assay:

Anti-tissue transglutaminase antibodies:

  • These antibodies are directed against the tissue transglutaminase-2 (tTG) antigen.[14]
  • They can be easily detected by ELISA[15]
  • Anti-tTG antibodies have high diagnostic accuracy.[16][17][18][19][20]

Antigliadin antibody assays

  • Antigliadin antibody (AGA) tests have low positive predictive value and are not recommended generally.[21]
  • The anti-deamidated gliadin peptide [DGP] assays have higher specificity and are thus preferred over antigliadin antibody (AGA) tests.[22][23]

NOTE:

  • Serum IgA EMA and IgA tTG have the highest diagnostic accuracy.
  • The IgA and IgG antigliadin antibody (AGA) are not recommended for estabilishing diagnosis as they have low accuracy and give more false positive results when compared with IgA tTG and IgA DGP assays.
  • The anti-deamidated gliadin peptide (DGP) assays also have high diagnostic accuracy.

Sensitivity and Specificity of Antibody testing:

Literature review has shown that IgA endomysial and IgA tissue transglutaminase antibodies have a sensitivity more than 95% and a specificity almost 100%. However variations in results are seen among different laboratories.[2][24][25][22][23][26][27]

Blood antibody tests for coeliac disease
Test sensitivity specificity
IgA enomysial antibody 85 to 98% 97 to 100%
IgA tissue transglutaminase antibody 90 to 98% 95 to 97%
IgA deamidated gliadin peptide 94% 99%
IgG deamidated gliadin peptide 92% 100%
Blood HLA tests for coeliac disease
Test sensitivity specificity
HLA-DQ2 94% 73%
HLA-DQ8 12% 81%


Algorithm for diagnostic testing of Celiac disease

Abbreviations:DGP: deamidated gliadin peptide; HLA: human leukocyte antigen; Ig: immunoglobulin; TTGA: tissue transglutaminase antibody.

Diagnostic testing in low probability celiac disease patients

 
 
 
 
 
 
 
 
Low Probability (<5%)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TTGA IgA ± IgA level
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positive TTGA
 
 
 
 
Negative TTGA
↓ IgA
 
 
 
 
Negative TTGA
Normal IgA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TTGA IgG ± DGP IgG
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If any positive
 
 
 
All negative
 
 
 
 
 
 
Biopsy
 
 
 
 
 
 
 
 
 
 
 
 
 
Celiac disease unlikely
 
 
 
 
 
 

Diagnostic testing in high probability celiac disease patients

 
 
 
 
 
 
 
High probability
(>5%)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Duodenal biopsy
• TTGA IgG
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Both negative
 
 
 
Both positive
 
 
 
Serology/biopsy disagreement
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Celiac disease unlikely
 
 
 
Celiac disease
 
 
 
Needs
• HLA DQ2 and DQ8 genotyping
•IgA level ± TTGA/DGP IgG
•work up for other causes of villous atrophy

References

  1. Anderson RP, Henry MJ, Taylor R, Duncan EL, Danoy P, Costa MJ, Addison K, Tye-Din JA, Kotowicz MA, Knight RE, Pollock W, Nicholson GC, Toh BH, Brown MA, Pasco JA (2013). "A novel serogenetic approach determines the community prevalence of celiac disease and informs improved diagnostic pathways". BMC Med. 11: 188. doi:10.1186/1741-7015-11-188. PMID 23981538.
  2. 2.0 2.1 Mäki M (1995). "The humoral immune system in coeliac disease". Baillieres Clin. Gastroenterol. 9 (2): 231–49. PMID 7549026.
  3. Bürgin-Wolff A, Gaze H, Hadziselimovic F, Huber H, Lentze MJ, Nusslé D, Reymond-Berthet C (1991). "Antigliadin and antiendomysium antibody determination for coeliac disease". Arch. Dis. Child. 66 (8): 941–7. PMC 1793455. PMID 1819255.
  4. Chorzelski TP, Beutner EH, Sulej J, Tchorzewska H, Jablonska S, Kumar V, Kapuscinska A (1984). "IgA anti-endomysium antibody. A new immunological marker of dermatitis herpetiformis and coeliac disease". Br. J. Dermatol. 111 (4): 395–402. PMID 6435666.
  5. Ferreira M, Davies SL, Butler M, Scott D, Clark M, Kumar P (1992). "Endomysial antibody: is it the best screening test for coeliac disease?". Gut. 33 (12): 1633–7. PMC 1379574. PMID 1487164.
  6. Grodzinsky E, Hed J, Skogh T (1994). "IgA antiendomysium antibodies have a high positive predictive value for celiac disease in asymptomatic patients". Allergy. 49 (8): 593–7. PMID 7653735.
  7. Kapuscinska A, Zalewski T, Chorzelski TP, Sulej J, Beutner EH, Kumar V, Rossi T (1987). "Disease specificity and dynamics of changes in IgA class anti-endomysial antibodies in celiac disease". J. Pediatr. Gastroenterol. Nutr. 6 (4): 529–34. PMID 3323442.
  8. Kumar V, Lerner A, Valeski JE, Beutner EH, Chorzelski TP, Rossi T (1989). "Endomysial antibodies in the diagnosis of celiac disease and the effect of gluten on antibody titers". Immunol. Invest. 18 (1–4): 533–44. PMID 2499536.
  9. Unsworth DJ, Brown DL (1994). "Serological screening suggests that adult coeliac disease is underdiagnosed in the UK and increases the incidence by up to 12%". Gut. 35 (1): 61–4. PMC 1374633. PMID 8307451.
  10. Ladinser B, Rossipal E, Pittschieler K (1994). "Endomysium antibodies in coeliac disease: an improved method". Gut. 35 (6): 776–8. PMC 1374877. PMID 8020804.
  11. Volta U, Molinaro N, de Franceschi L, Fratangelo D, Bianchi FB (1995). "IgA anti-endomysial antibodies on human umbilical cord tissue for celiac disease screening. Save both money and monkeys". Dig. Dis. Sci. 40 (9): 1902–5. PMID 7555440.
  12. Kárpáti S, Meurer M, Stolz W, Bürgin-Wolff A, Braun-Falco O, Krieg T (1992). "Ultrastructural binding sites of endomysium antibodies from sera of patients with dermatitis herpetiformis and coeliac disease". Gut. 33 (2): 191–3. PMC 1373928. PMID 1541414.
  13. Valeski JE, Kumar V, Beutner EH, Lerner A, Chorzelski TP (1990). "Immunology of celiac disease: tissue and species specificity of endomysial and reticulin antibodies". Int. Arch. Allergy Appl. Immunol. 93 (1): 1–7. PMID 2128295.
  14. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D (1997). "Identification of tissue transglutaminase as the autoantigen of celiac disease". Nat. Med. 3 (7): 797–801. PMID 9212111.
  15. Tonutti E, Visentini D, Bizzaro N, Caradonna M, Cerni L, Villalta D, Tozzoli R (2003). "The role of antitissue transglutaminase assay for the diagnosis and monitoring of coeliac disease: a French-Italian multicentre study". J. Clin. Pathol. 56 (5): 389–93. PMC 1769943. PMID 12719462.
  16. Dieterich W, Laag E, Schöpper H, Volta U, Ferguson A, Gillett H, Riecken EO, Schuppan D (1998). "Autoantibodies to tissue transglutaminase as predictors of celiac disease". Gastroenterology. 115 (6): 1317–21. PMID 9834256.
  17. Sulkanen S, Halttunen T, Laurila K, Kolho KL, Korponay-Szabó IR, Sarnesto A, Savilahti E, Collin P, Mäki M (1998). "Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease". Gastroenterology. 115 (6): 1322–8. PMID 9834257.
  18. Troncone R, Maurano F, Rossi M, Micillo M, Greco L, Auricchio R, Salerno G, Salvatore F, Sacchetti L (1999). "IgA antibodies to tissue transglutaminase: An effective diagnostic test for celiac disease". J. Pediatr. 134 (2): 166–71. PMID 9931524.
  19. Hopper AD, Cross SS, Hurlstone DP, McAlindon ME, Lobo AJ, Hadjivassiliou M, Sloan ME, Dixon S, Sanders DS (2007). "Pre-endoscopy serological testing for coeliac disease: evaluation of a clinical decision tool". BMJ. 334 (7596): 729. doi:10.1136/bmj.39133.668681.BE. PMC 1847864. PMID 17383983.
  20. Hopper AD, Hadjivassiliou M, Hurlstone DP, Lobo AJ, McAlindon ME, Egner W, Wild G, Sanders DS (2008). "What is the role of serologic testing in celiac disease? A prospective, biopsy-confirmed study with economic analysis". Clin. Gastroenterol. Hepatol. 6 (3): 314–20. doi:10.1016/j.cgh.2007.12.008. PMID 18328437.
  21. Corrao G, Corazza GR, Andreani ML, Torchio P, Valentini RA, Galatola G, Quaglino D, Gasbarrini G, di Orio F (1994). "Serological screening of coeliac disease: choosing the optimal procedure according to various prevalence values". Gut. 35 (6): 771–5. PMC 1374876. PMID 8020803.
  22. 22.0 22.1 Sugai E, Vázquez H, Nachman F, Moreno ML, Mazure R, Smecuol E, Niveloni S, Cabanne A, Kogan Z, Gómez JC, Mauriño E, Bai JC (2006). "Accuracy of testing for antibodies to synthetic gliadin-related peptides in celiac disease". Clin. Gastroenterol. Hepatol. 4 (9): 1112–7. doi:10.1016/j.cgh.2006.05.004. PMID 16860613.
  23. 23.0 23.1 Prince HE (2006). "Evaluation of the INOVA diagnostics enzyme-linked immunosorbent assay kits for measuring serum immunoglobulin G (IgG) and IgA to deamidated gliadin peptides". Clin. Vaccine Immunol. 13 (1): 150–1. doi:10.1128/CVI.13.1.150-151.2006. PMC 1356631. PMID 16426013.
  24. Abrams JA, Brar P, Diamond B, Rotterdam H, Green PH (2006). "Utility in clinical practice of immunoglobulin a anti-tissue transglutaminase antibody for the diagnosis of celiac disease". Clin. Gastroenterol. Hepatol. 4 (6): 726–30. doi:10.1016/j.cgh.2006.02.010. PMID 16630760.
  25. Swallow K, Wild G, Sargur R, Sanders DS, Aziz I, Hopper AD, Egner W (2013). "Quality not quantity for transglutaminase antibody 2: the performance of an endomysial and tissue transglutaminase test in screening coeliac disease remains stable over time". Clin. Exp. Immunol. 171 (1): 100–6. doi:10.1111/cei.12000. PMC 3530101. PMID 23199329.
  26. Kelly CP, Feighery CF, Gallagher RB, Gibney MJ, Weir DG (1991). "Mucosal and systemic IgA anti-gliadin antibody in celiac disease. Contrasting patterns of response in serum, saliva, and intestinal secretions". Dig. Dis. Sci. 36 (6): 743–51. PMID 2032515.
  27. Rostami K, Kerckhaert J, Tiemessen R, von Blomberg BM, Meijer JW, Mulder CJ (1999). "Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice". Am. J. Gastroenterol. 94 (4): 888–94. doi:10.1111/j.1572-0241.1999.983_f.x. PMID 10201452.